| | | |   | | | | By Ed Silverman VINCENZO PINTO/AFP via Getty Images The proposal was made in response to controversy over the extent to which Covid-19 vaccines were being made available to poorer countries. Read More | | By Adam Feuerstein and Damian Garde Steven Senn/AP The storied company is moving forward with a lame-duck CEO, an interim chief scientist, and a board with a long history of gridlock. Read More | | By Adam Feuerstein and Damian Garde Jessica Rinaldi/The Boston Globe Drug companies rarely stop marketing a new medicine voluntarily, which makes Biogen’s abandonment of Aduhelm an almost unprecedented setback. Read More | | Sponsor content by REGULATORY AFFAIRS PROFESSIONALS SOCIETY Is understanding the practical applications of regulatory requirements critical to your job? Get up-to-date knowledge of new regulations and their implications for pharmaceutical and biologics regulatory affairs with a Regulatory Affairs Certificate in pharmaceuticals from RAPS. Delve into the latest information with self-paced online courses covering issues associated with bringing drugs to market and the regulatory profession. The certificate program features a curriculum of four core courses and five electives, chosen from dozens of options spanning the topical areas of quality, clinical, biologics, and pharmaceuticals. Learn more. | | By Els Torreele JOHAN ORDONEZ/AFP via Getty Images Moderna, Pfizer, and J&J investors decided they knew better than the WHO's director-general about how to tackle the continuing pandemic. Read More | |
No comments